Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.42 |
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25511366 | 1.00 | CYP3A4 (0.49) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL26288028 | 0.94 | CYP3A4 (0.42) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL26288030 | 0.94 | CYP3A4 (0.42) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL21283660 | 0.93 | CYP3A4 (0.42) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL25511546 | 0.91 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL24088384 | 0.90 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL26282459 | 0.90 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL25804205 | 0.90 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL24120253 | 0.90 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL27439278 | 0.90 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2015081133-A2 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | CYP3A4 3731/4885CYP2C9 4137/4885BTN3A1 3859/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | CYP3A4 3731/4885CYP2C9 4137/4885BTN3A1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.